Risk of drug dependence and abuse posed by barbiturate-containing analgesics

Canadian Journal of Clinical Pharmacology

Volumn 6, Issue 1, 1999, Pages 18-25

  Sellers, Edward M ^a   Hoornweg, Karen ^b   Busto, Usoa E ^b   Romach, Myroslava K ^b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b NONE

Author keywords

Addiction; Analgesia; Barbiturates; Dependence

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; BUTALBITAL; CAFFEINE; COCODAMOL; CODEINE; MEPROBAMATE; MORPHINE; NOVOGESIC; PARACETAMOL; PENTOBARBITAL; PHENACETIN; PHENOBARBITAL; SECOBARBITAL; TECNAL; TRIAZOLAM; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; CLINICAL TRIAL; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL LITERATURE; ORAL DRUG ADMINISTRATION; PAIN; PRESCRIPTION; PUBLIC HEALTH; RESPIRATION DEPRESSION; SOCIAL PROBLEM; TOOTH PAIN;

EID: 0032891940     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Report of the Expert Advisory Committee on Short and Intermediate Acting Barbiturates, IL No 718. Ottawa: Health Protection Branch, Health and Welfare Canada, 1987.
2. Fiorinal. In: Gillis MC, ed. Compendium of Pharmaceuticals and Specialties, 32nd edn. Ottawa: Canadian Pharmaceutical Association, 1997:576-7.
3. Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiologic study of headache among adolescents and young adults. JAMA 1989;261:2211-6.
4. Rall TW. Sedatives and hypnotics. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 8th edn. New York: Pergamon Press, 1990:345-82.
5. Reynolds JEF, ed. Martindale. The Extra Pharmacopoeia, 28th edn. London: The Pharmaceutical Press, 1982:795.
6. Pechnick RN, Terman GW, Liebeskind JC. Potentiation of pentobarbital sleeping time by the acute and chronic administration of morphine. NIDA Res Monogr 1987;76:233-9.
7. Carlsson KH, Junna I. Interaction of pentobarbital and morphine in the tail-flick test performed on rats: Synergism at the spinal and antagonism at the supraspinal level. Neurosci Lett 1986;71:356-60.
8. Kissin I, Mason JO, Bradley EL Jr. Morphine and fentanyl interactions with thiopental in relation to movement response to noxious stimulation. Anesth Analg 1986;65:1149-54.
9. Kissin I, Mason JO, Bradley EL Jr. Morphine and fentanyl hypnotic interactions with thiopental. Anesthesiology 1987;67:331-5.
10. Pontani RB, Vadlamani NL, Misra AL. Potentiation of morphine analgesia by subanesthetic doses of pentobarbital. Pharmacol Biochem Behav 1985;22:395-8.
11. Geller EB, Durlofsky L, Cowan A, Harakal C, Adler MW. The effect of pentobarbital on the antinociceptive action of morphine in morphine-tolerant and non-tolerant rats. Life Sci 1979;25:139-46.
12. Roca DJ, Schiller GD, Friedman L, Rozenberg I, Gibbs TT. Gamma-aminobutyric acidA receptor regulation in culture: Altered allosteric interactions following prolonged exposure to benzodiazepines, barbiturates, and methylxanthines. Mol Pharmacol 1990;37:710-9.
13. Beaver WT. Combination analgesics. Am J Med 1984;77:38-53.
14. MacDonald C, Ehrenreich KA. A double-blind comparison of two analgesics with placebo control. Can Med Assoc J 1966;95:1072-5.
15. Friedman AP, DiSerio FJ. Symptomatic treatment of chronically recurring tension headache: A placebo-controlled, multicenter investigation of Fioricet® and acetaminophen with codeine. Clin Ther 1987;10:69-81.
16. Friedman AP. Assessment of Fiorinal® with codeine in the treatment of tension headache. Clin Ther 1986;8:703-21.
17. Desjardins PJ, Cooper SA, Finizio T. Efficacy of low dose combination analgesics: Acetaminophen/codeine, aspirin/ butalbital/caffeine/codeine, and placebo in oral surgery pain. Anesth Prog 1986;33:143-6.
18. Forbes JA, Jones KF, Smith WK, Gongloff CM. Analgesic effect of an aspirin-codeine-butalbital-caffeine combination and an acetaminophen-codeine combination in postoperative oral surgery pain. Pharmacotherapy 1986;6:240-7.
19. Moertel CG, Ahmann DL, Taylor WF. Relief of pain by oral medications. JAMA 1974;229:55-9.
20. Harvey SC. Hypnotics and sedatives. In: Gilman AG, Goodman LS, Rail TW, Murad F, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 7th edn. New York: MacMillan Publishing Company, 1985:339-71.
21. Reynolds JEF, ed. Martindale. The Extra Pharmacopoeia, 29th edn. London: The Pharmaceutical Press, 1989:706-11.
22. Gosselin RE, Smith RP, Hodge HC, eds. Clinical Toxicology of Commercial Products, 5th edn. Baltimore: Williams & Wilkins, 1984:52-61.
23. Rumack BH, Lovejoy FH Jr. Clinical toxicology. In: Klaassen CD, Amdur MO, Doull J, eds. Casarett and Doull's Toxicology. New York: MacMillan Publishing Company, 1986:879-901.
24. Gosselin RE, Smith RP, Hodge HC, eds. Clinical Toxicology of Commercial Products, 5th edn. Baltimore: Williams & Wilkins, 1984:368-75.
25. Gosselin RE, Smith RP, Hodge HC, eds. Clinical Toxicology of Commercial Products, 5th edn. Baltimore: Williams & Wilkins, 1984:239.
26. Leslie PJ, Dyson EH, Proudfoot AT. Opiate toxicity after self poisoning with aspirin and codeine. Br Med J (Clin Res Ed) 1986;292:96.
27. Dreisbach RH. Handbook of Poisoning: Prevention, Diagnosis and Treatment, 11th edn. Los Altos: Lange Medical Publications, 1983:356.
28. Gosselin RE, Smith RP, Hodge HC, eds. Clinical Toxicology of Commercial Products, 5th edn. Baltimore: Williams & Wilkins, 1984:243.
29. Edwards G, Arif A, Hadgson R. Nomenclature and classification of drug- and alcohol-related problems: A WHO memorandum. Bull WHO 1981;59:225-42.
30. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington: American Psychiatric Association, 1994.
32. Sellers EM, Ciraulo DA, DuPont RL, et al. Alprazolam and benzodiazepine withdrawal. J Clin Psychiatry 1993;54 (10 Suppl):64-75.
33. Romach MK, Somer GR, Sobell LC, Sobell MB, Kaplan HL, Sellers EM. Characteristics of long-term alprazolam users in the community. J Clin Psychopharmacol 1992;12:316-21.
34. Martin WR, Thompson WO, Fraser HF. Comparison of graded single intramuscular doses of morphine and pentobarbital in man. Clin Pharmacol Ther 1974;15:623-30.
35. McClane TK, Martin WR. Subjective and physiologic effects of morphine, pentobarbital and meprobamate. Clin Pharmacol Ther 1976;20:192-8.
36. Zawertailo L, Busto U, Kaplan HL, Sellers EM. Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. J Clin Psychopharmacol 1995;15:117-24.
37. Busto U, Sellers EM. Pharmacokinetic determinants of drug abuse and dependence: A conceptual perspective. Clin Pharmacokinet 1986;11:144-53.
38. Wulff MH. The barbiturate withdrawal syndrome: A clinical and electroencephalographic study. Electroencephalogr Clin Neurophysiol Suppl 1959;14:11-173.
39. Fraser HF, Wikler A, Essig CF, Isbell H. Degree of physical dependence induced by secobarbital or pentobarbital. JAMA 1958;166:126-9.
40. Yamada M, Ota T. Analgesic dependence leading to intoxication -A report of five cases. Folia Psychiatr Neurol Jpn 1978;32:563-7.
41. Epstein RS. Withdrawal symptoms from chronic use of low-dose barbiturates. Am J Psychiatry 1980;137:107-8.
42. Preskorn SH, Schwin RL, McKnelly WV. Analgesic abuse and the barbiturate abstinence syndrome. JAMA 1980;244:369-70.
43. Devenyi P, Rideout J, Schneiderman J. Abuse of a commonly prescribed analgesic preparation. Can Med Assoc J 1985;133:294-6.
44. Sands GH. A protocol for butalbital, aspirin and caffeine (BAC) detoxification in headache patients. Headache 1990;30:491-6.
45. Aladin F, Naranjo CA, Busto U. Butalbital (B), a new drug of abuse. Clin Pharmacol Ther 1988;43:IC3. (Abst)
46. Medina JL, Diamond S. Drug dependency in patients with chronic headaches. Headache 1977;17:12-4.
47. Korcok M. Canadian government study shows big rise in Canadian use of several narcotics. Can Med Assoc J 1979;120:1270-1.
48. Isaac P, Seto W, Lanctôt KL, Busto UE. Use and abuse of prescription opioids in Canada 1978 to 1989. Can J Clin Pharmacol 1995;2:81-6.
49. Carlisle JR, Wilford BB, Goldman B. Frustrating prescription drug seekers. Emerg Med Rep 1988;9:203-10.
50. McCoy GB. Prescription forgery in everyday practice. Pharm Pract 1990;6:37-40.
51. Aladin F, Naranjo CA, Busto U. Butalbital, a new drug of abuse. Clin Pharmacol Ther 1988;43:143.
52. Drost ML, Walter L. Blood and plasma concentrations of bulalbital following single oral doses in man. J Anal Toxicol 1988;12:322-4.
53. Kalant H, Roschlau WHE, eds. Drug Principles of Medical Pharmacology, 5th edn. Toronto: BC Decker Inc, 1989:67-71.
54. Nelson E, Powell JR, Conrad K, et al. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol 1982;22:141-8.
55. IMS Canada. The top 200 drugs of 1996. Pharm Pract 1996;12:67-79.
56. Therriault I. The pharmacy practice 200: An exclusive IMS report on the top 200 drugs of '92. Pharm Pract 1992;8:27-34.